Pharmaceutical company, Berg, has partnered with the Icahn School of Medicine at Mount Sinai (Icahn), in order to implement a “data driven, biological research approach” to medicine, which they claim could change the face of health care. Berg and Icahn will use Berg’s Interrogative Biology platform to analyze biological data from human beings. The Interrogative Biology platform combines a patient’s biological data with his clinical and demographic data in order to create a biomarker library. A biomarker is a quantifiable substance in an organism that predicts disease or infection.
The biomarker library is intended to allow the partners to detect disease patterns in a given population. The identification of disease patterns would help doctors, insurance companies and government agencies identify the most efficacious diagnostics and treatments for patients.